ABEO · CIK 0000318306
What Abeona Therapeutics Inc. told the SEC could break it.
Abeona's disclosures are those of a company just crossing into commercialization on the strength of a single product. Its commercial revenue depends almost entirely on ZEVASKYN, an autologous gene therapy approved by the FDA in April 2025 that made its first sale only in the fourth quarter ($2.4 million), so its near-term fortunes hinge on uptake of that one therapy. It is still burning cash — it has run negative operating cash flows since inception and expects to keep spending heavily — and funds itself through a $75 million Jefferies at-the-market equity program (about $51.5 million remaining) and a convertible secured loan from Avenue. As a gene-therapy maker, its products are also regulated by the FDA under the FDCA and Public Health Service Act, exposing it to approval-timing and post-market surveillance risk.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- negative operating cash flow; reliance on ATM equity and Avenue loanmedium
Abeona has incurred negative operating cash flows since inception and expects to keep spending substantial funds; it funds itself through a $75M Jefferies ATM (≈$51.5M remaining) and an Avenue secured loan with a conversion feature.
“Since our inception and excluding the gain on sale of our priority review voucher, we have incurred negative cash flows from operations and have expended, and expect to continue to expend, substantial funds”
SEC filing →As of 2026
Regulatory & policy
- FDA biologic/gene-therapy regulation (BLA/PDUFA)medium
Abeona's gene-therapy products are regulated by the FDA under the FDCA and PHSA, including BLA review under PDUFA goal dates the FDA does not always meet — creating approval-timing and post-market surveillance risk.
“In the United States, the FDA regulates biologic products including gene therapy products under the Federal Food, Drug, and Cosmetic Act (“FDCA”), the Public Health Service Act (“PHSA”), and regulations implementing these laws.”
SEC filing →As of 2026
Other disclosures
- early single-product commercialization (ZEVASKYN launched Q4 2025)low
Abeona's commercial revenue depends almost entirely on ZEVASKYN, an autologous gene therapy FDA-approved April 2025 with its first sale only in Q4 2025 ($2.4M product revenue), so commercial uptake risk for a single product is high.
“After FDA approval of ZEVASKYN ® in April 2025, we began commercial marketing and made our first product sale in Q4 2025.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“aysha relating to Taysha's development program for TSHA-118 for CLN1 disease.”
Cited →Ultragenyx Pharmaceutical Inc.
“Under the License Agreement, Ultragenyx assumed responsibility for the ABO-102 program from the Company, with the exclusive right to develop, manufacture, and commercialize ABO-102 worldwide.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch